Forskolin-DataSheet-生命科學試劑-MedChemExpress_第1頁
Forskolin-DataSheet-生命科學試劑-MedChemExpress_第2頁
Forskolin-DataSheet-生命科學試劑-MedChemExpress_第3頁
Forskolin-DataSheet-生命科學試劑-MedChemExpress_第4頁
Forskolin-DataSheet-生命科學試劑-MedChemExpress_第5頁
全文預覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領(lǐng)

文檔簡介

Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemEForskolinCat.No.:HY-15371CASNo.:66575-29-9分?式:C??H??O?分?量:410.5作?靶點:AdenylateCyclase;FXR;Autophagy作?通路:GPCR/GProtein;MetabolicEnzyme/Protease;Autophagy儲存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfromlight)溶解性數(shù)據(jù)體外實驗DMSO:100mg/mL(243.61mM;Needultrasonic)掃描?維碼,H2O:<0.1mg/mL(insoluble)運?溶解?案計算器獲得適合您實驗體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.4361mL12.1803mL24.3605mL5mM0.4872mL2.4361mL4.8721mL10mM0.2436mL1.2180mL2.4361mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存?式和期限。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液,再依次添加助溶劑:為保證實驗結(jié)果的可靠性,澄的儲備液可以根據(jù)儲存條件,適當保存;體內(nèi)實驗的?作液,建議您現(xiàn)?現(xiàn)配,當天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的?式助溶1.請依序添加每種溶劑:10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(6.09mM);Clearsolution此?案可獲得≥2.5mg/mL(6.09mM,飽和度未知)的澄溶液。以1mL?作液為例,取100μL25.0mg/mL的澄DMSO儲備液加到400μLPEG300中,混合均勻;向上述2.體系中加?50μLTween-80,混合均勻;然后繼續(xù)加?450μL?理鹽?定容?1mL。請依序添加每種溶劑:10%DMSO90%cornoil1/4www.MedChemEwww.MedChemESolubility:≥2.5mg/mL(6.09mM);Clearsolution此?案可獲得≥2.5mg/mL(6.09mM,飽和度未知)的澄溶液,此?案不適?于實驗周期在半個?以上的實驗。以1mL?作液為例,取100μL25.0mg/mL的澄DMSO儲備液加到900μL??油中,混合均勻。BIOLOGICALACTIVITY?物活性Forskolin(Coleonol)?種有效的腺苷酸環(huán)化酶(adenylatecyclase)激活劑,對于I型腺苷酸環(huán)化酶,IC50為41nM,EC50為0.5μM。Forskolin也?種細胞內(nèi)cAMP形成的誘導劑。Forskolin誘導多種細胞類型的分化并激活孕烷X受體(PXR)和FXR。Forskolin對?臟產(chǎn)?正性肌?作?,并具有??板抗凝集和降壓作?。Forskolin也可誘導細胞?噬(autophagy)。IC50&TargetIC50:41nM(Adenylylcyclase)[1]EC50:0.5μM(Adenylylcyclase)[1]體外研究Forskolin(Coleonol)isalsoapotentexosomebiogenesisand/orsecretionactivatorinprostatecancer(PC)cells[8].Forskolin(Fsk)isanaturallyoccurringditerpeneisolatedfromColeusforskholii,directlyactivatesadenylylcyclase(AC)throughitscatalyticsubunittoincreaseintracellularlevelsofcyclicadenosinemonophosphate(cAMP)[1].Forskolin(Fsk)affectstheproliferationofthehumanT-celllinessuchasKit225andMT-2.ForskolintreatmentinhibitstheproliferationofbothKit225andMT-2cellsinadose-dependentmannerwithanIC50equalto~5μMFsk.Forskolintreatment(10-100μM)increasescAMPilevels~5-to20-foldabovebasallevels,whichreachemaximumlevelsbetween50-100μMForskolin[6].體內(nèi)研究TheForskolin(Coleonol)-treatedMrp4-/-miceshowsanincreasednumberofKi67-positiveandcleavedcaspase3-positiveECs,asignificantdecreaseintheamountofpericytecoverage,andareducednumberofemptysleeves.Inpupsexposedtohyperoxia(75%oxygen)fromP7toP12,theMrp4-/-miceshowsasignificantincreaseintheunvascularizedretinalarea[2].Theaveragebloodglucoseinthehealthyratgroupis102.12±1.94mg/dL,101.25±3.56forcontrolgroupand103±2.08inforskolingroup.Thedatashowsthatglucoselevelsattheendofthestudyarelowerinforskolingroup,withasignificantdifferenceaccordingtothestatisticaltestsapplied(p=0.03)[7].PROTOCOLCellAssay[2]QuiescentKit225orMT-2cellsareseededinto96-wellplatesat5×104cellsperwell.Cellsarethenpretreatedfor1hwith1%DMSO(vehicle)orForskolinat1,5,10,25,50,and100μMconcentrations.ThecellsarestimulatedwithIL-2andculturedforanadditional20hat37°C.Controlcellsaretreatedwith1%DMSOfor20h.Duringthefinal4hofincubation,thecellsarepulsedwith[3H]thymidineataconcentrationof0.5μCi/200μL.Cellsareharvestedontofiberglassfiltersandanalyzedusingliquidscintillationcounting[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.AnimalMice[3]2/4www.MedChemEwww.MedChemEAdministration[3][4]C57BL/6Jmiceareused.Mrp4-knockoutmice,whichareestablishedandrepeatedlybackcrossedtotheC57BL/6Jmice.Forskolinisinjectedintraperitoneallyintoneonatalmiceatpostnataldays4(P4)and5(P5).MiceinjectedwithDMSOserveasthecontrols.ThetreatedmiceareeuthanizedatP6,andtheirretinasareisolatedforwhole-mountimmunohistochemistry(IHC).TheeffectofdifferentconcentrationsofForskolinonthesurvivalrateandretinalvasculatureisfirsttested,andtheoptimalconcentrationisdetermined,1.0μg/50μL(0.3mg/kg)atP4and1.5μg/50μL(0.5mg/kg)atP5,usedtocomparetheretinalvascularphenotypesbetweenWTmiceandMrp4-deficientmice.Rats[4]MaleWistarrats,aged10-14weeksold,withameanweightof300g±50g,aredividedintofourgroups;19areexperimentallyinducedtodevelopdiabetes,and8aremaintainedinahealthycondition.BothdiabeticandhealthyratsreceivenoForskolin(control),or6mg/kgperdayofForskolin,administeredorallyfor8weeks.BloodglucoselevelsaredeterminedineachgroupbeforeandafterForskolintreatment.Thediabeticratsaretestedtwoweeksafterconfirmingthepresenceofdiabetes(threeweeksaftertheinduction)andaftereightweeksofthedesignatedtreatment.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻?SciTranslMed.2020May6;12(542):eaba0769.?SignalTransductTargetTher.2021Feb28;6(1):91.?Biomaterials.2018Dec6;193:30-46.?BrJPharmacol.2019Aug;176(16):2962-2976.?JExpClinCancerRes.2019Sep13;38(1):404.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].RobbinsJD,etal.Forskolincarbamates:bindingandactivationstudieswithtypeIadenylylcyclase.JMedChem.1996Jul5;39(14):2745-52.[2].RodriguezG,etal.Forskolin-induciblecAMPpathwaynegativelyregulatesT-cellproliferationbyuncouplingtheinterleukin-2receptorcomplex.JBiolChem.2013Mar8;288(10):7137-46.[3].MatsumiyaW,etal.ForskolinmodifiesretinalvasculardevelopmentinMrp4-knockoutmice.InvestOphthalmolVisSci.2012Dec7;53(13):8029-35.[4].Ríos-SilvaM,etal.Effectofchronicadministrationofforskolinonglycemiaandoxidativestressinratswithandwithoutexperimentaldiabetes.IntJMedSci.2014Mar11;11(5):448-52.[5].MayatiA,etal.FunctionalpolarizationofhumanhepatomaHepaRGcellsinresponsetoforskolin.SciRep.2018Oct31;8(1):16115.[6].AwadJA,etal.Interactionsofforskolinandadenylatecyclase.EffectsonsubstratekineticsandprotectionagainstinactivationbyheatandN-ethylmaleimide.JBiolChem

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
  • 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論